Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on advancing innovative therapies, has received U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application for Lucid-MS, clearing the way for Phase 2 clinical testing of its multiple sclerosis (MS) candidate. The planned randomized, double-blind, placebo-controlled study will evaluate the drug's efficacy, safety, and tolerability in patients with MS, with researchers assessing clinical symptoms and changes visible through brain imaging. Unlike many existing MS therapies that target the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage. This distinct mechanism could offer a different therapeutic approach for a disease that affects millions worldwide.
The compound previously completed Phase 1 trials in healthy volunteers, where the company reported a favorable safety profile and good tolerability. The FDA's clearance of the IND application marks a critical step forward for Quantum BioPharma, which is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
For investors, this milestone could signal significant potential. The MS market is large and growing, and a therapy that works differently from existing treatments could capture substantial share if approved. The FDA's decision to allow Phase 2 testing suggests the agency sees promise in the approach. Quantum BioPharma's stock could react positively to the news, as clinical progress is a key driver in biotech valuations. For patients, Lucid-MS represents a potential new option that might complement or replace current therapies, particularly for those who do not respond well to immune-modulating drugs.
To view the full article, visit https://ibn.fm/g5EXE. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. Quantum BioPharma also retains ownership of 19.48% of Unbuzzd Wellness Inc., which markets UNBUZZD™, an OTC product, at www.unbuzzd.com. The agreement includes royalty payments to Quantum of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
BioMedWire, a specialized communications platform for the biotechnology and life sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers. For more information, visit BioMedWire. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
